KalVista Pharmaceuticals Inc KALV
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
KalVista Appoints Brian Piekos as Chief Financial Officer
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks
KalVista Pharma Hits Targeted Number of Patients in Sebetralstat Trial